カテゴリー： QYResearch, 世界, 医療/バイオ

世界の副腎白質ジストロフィー治療市場インサイト及び予測（経口剤、経皮吸収型製剤）

◆英語タイトル：Global Adrenoleukodystrophy Treatment Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09215 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：128 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、副腎白質ジストロフィー治療のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に副腎白質ジストロフィー治療の世界市場のxxx％を占める「経口剤」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
副腎白質ジストロフィー治療の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの副腎白質ジストロフィー治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

副腎白質ジストロフィー治療のグローバル主要企業には、bluebird bio、Orpheris、MedDay Pharmaceuticals、MINORYX THERAPEUTICS SL、Pfizer、Amgen、AstraZeneca、Abbott、agtc、ReceptoPharm、The Myelin Project、SOM Biotech、Viking Therapeutics、Nutra Pharma Corporation、Genetix Biotech、Magenta Therapeutics、NeuroVia、Novartis、CELGENE CORPORATION、Jazz Pharmaceuticals、Sanofiなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

副腎白質ジストロフィー治療市場は、種類と用途によって区分されます。世界の副腎白質ジストロフィー治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
経口剤、経皮吸収型製剤

【用途別セグメント】
病院、診療所、在宅医療

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 副腎白質ジストロフィー治療製品概要
- 種類別市場（経口剤、経皮吸収型製剤）
- 用途別市場（病院、診療所、在宅医療）
- 調査の目的
・エグゼクティブサマリー
- 世界の副腎白質ジストロフィー治療販売量予測2017-2028
- 世界の副腎白質ジストロフィー治療売上予測2017-2028
- 副腎白質ジストロフィー治療の地域別販売量
- 副腎白質ジストロフィー治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別副腎白質ジストロフィー治療販売量
- 主要メーカー別副腎白質ジストロフィー治療売上
- 主要メーカー別副腎白質ジストロフィー治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（経口剤、経皮吸収型製剤）
- 副腎白質ジストロフィー治療の種類別販売量
- 副腎白質ジストロフィー治療の種類別売上
- 副腎白質ジストロフィー治療の種類別価格
・用途別市場規模（病院、診療所、在宅医療）
- 副腎白質ジストロフィー治療の用途別販売量
- 副腎白質ジストロフィー治療の用途別売上
- 副腎白質ジストロフィー治療の用途別価格
・北米市場
- 北米の副腎白質ジストロフィー治療市場規模（種類別、用途別）
- 主要国別の副腎白質ジストロフィー治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの副腎白質ジストロフィー治療市場規模（種類別、用途別）
- 主要国別の副腎白質ジストロフィー治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の副腎白質ジストロフィー治療市場規模（種類別、用途別）
- 主要国別の副腎白質ジストロフィー治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の副腎白質ジストロフィー治療市場規模（種類別、用途別）
- 主要国別の副腎白質ジストロフィー治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの副腎白質ジストロフィー治療市場規模（種類別、用途別）
- 主要国別の副腎白質ジストロフィー治療市場規模（トルコ、サウジアラビア）
・企業情報
bluebird bio、Orpheris、MedDay Pharmaceuticals、MINORYX THERAPEUTICS SL、Pfizer、Amgen、AstraZeneca、Abbott、agtc、ReceptoPharm、The Myelin Project、SOM Biotech、Viking Therapeutics、Nutra Pharma Corporation、Genetix Biotech、Magenta Therapeutics、NeuroVia、Novartis、CELGENE CORPORATION、Jazz Pharmaceuticals、Sanofi
・産業チェーン及び販売チャネル分析
- 副腎白質ジストロフィー治療の産業チェーン分析
- 副腎白質ジストロフィー治療の原材料
- 副腎白質ジストロフィー治療の生産プロセス
- 副腎白質ジストロフィー治療の販売及びマーケティング
- 副腎白質ジストロフィー治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 副腎白質ジストロフィー治療の産業動向
- 副腎白質ジストロフィー治療のマーケットドライバー
- 副腎白質ジストロフィー治療の課題
- 副腎白質ジストロフィー治療の阻害要因
・主な調査結果

Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
Market Analysis and Insights: Global Adrenoleukodystrophy Treatment Market
The global Adrenoleukodystrophy Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Oral Drugs accounting for % of the Adrenoleukodystrophy Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Adrenoleukodystrophy Treatment market size is valued at US$ million in 2021, while the North America and Europe Adrenoleukodystrophy Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Adrenoleukodystrophy Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Adrenoleukodystrophy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Adrenoleukodystrophy Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Adrenoleukodystrophy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Adrenoleukodystrophy Treatment market.
Global Adrenoleukodystrophy Treatment Scope and Market Size
Adrenoleukodystrophy Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Adrenoleukodystrophy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral Drugs
Parenteral Drugs
Segment by Application
Hospital
Clinic
Home Care
By Company
bluebird bio
Orpheris
MedDay Pharmaceuticals
MINORYX THERAPEUTICS SL
Pfizer
Amgen
AstraZeneca
Abbott
agtc
ReceptoPharm
The Myelin Project
SOM Biotech
Viking Therapeutics
Nutra Pharma Corporation
Genetix Biotech
Magenta Therapeutics
NeuroVia
Novartis
CELGENE CORPORATION
Jazz Pharmaceuticals
Sanofi
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral Drugs
1.2.3 Parenteral Drugs
1.3 Market by Application
1.3.1 Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Adrenoleukodystrophy Treatment Market Perspective (2017-2028)
2.2 Adrenoleukodystrophy Treatment Growth Trends by Region
2.2.1 Adrenoleukodystrophy Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Adrenoleukodystrophy Treatment Historic Market Size by Region (2017-2022)
2.2.3 Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2023-2028)
2.3 Adrenoleukodystrophy Treatment Market Dynamics
2.3.1 Adrenoleukodystrophy Treatment Industry Trends
2.3.2 Adrenoleukodystrophy Treatment Market Drivers
2.3.3 Adrenoleukodystrophy Treatment Market Challenges
2.3.4 Adrenoleukodystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue
3.1.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue (2017-2022)
3.1.2 Global Adrenoleukodystrophy Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Adrenoleukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adrenoleukodystrophy Treatment Revenue
3.4 Global Adrenoleukodystrophy Treatment Market Concentration Ratio
3.4.1 Global Adrenoleukodystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Treatment Revenue in 2021
3.5 Adrenoleukodystrophy Treatment Key Players Head office and Area Served
3.6 Key Players Adrenoleukodystrophy Treatment Product Solution and Service
3.7 Date of Enter into Adrenoleukodystrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenoleukodystrophy Treatment Breakdown Data by Type
4.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Type (2017-2022)
4.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2023-2028)
5 Adrenoleukodystrophy Treatment Breakdown Data by Application
5.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Application (2017-2022)
5.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Adrenoleukodystrophy Treatment Market Size (2017-2028)
6.2 North America Adrenoleukodystrophy Treatment Market Size by Type
6.2.1 North America Adrenoleukodystrophy Treatment Market Size by Type (2017-2022)
6.2.2 North America Adrenoleukodystrophy Treatment Market Size by Type (2023-2028)
6.2.3 North America Adrenoleukodystrophy Treatment Market Share by Type (2017-2028)
6.3 North America Adrenoleukodystrophy Treatment Market Size by Application
6.3.1 North America Adrenoleukodystrophy Treatment Market Size by Application (2017-2022)
6.3.2 North America Adrenoleukodystrophy Treatment Market Size by Application (2023-2028)
6.3.3 North America Adrenoleukodystrophy Treatment Market Share by Application (2017-2028)
6.4 North America Adrenoleukodystrophy Treatment Market Size by Country
6.4.1 North America Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
6.4.2 North America Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Adrenoleukodystrophy Treatment Market Size (2017-2028)
7.2 Europe Adrenoleukodystrophy Treatment Market Size by Type
7.2.1 Europe Adrenoleukodystrophy Treatment Market Size by Type (2017-2022)
7.2.2 Europe Adrenoleukodystrophy Treatment Market Size by Type (2023-2028)
7.2.3 Europe Adrenoleukodystrophy Treatment Market Share by Type (2017-2028)
7.3 Europe Adrenoleukodystrophy Treatment Market Size by Application
7.3.1 Europe Adrenoleukodystrophy Treatment Market Size by Application (2017-2022)
7.3.2 Europe Adrenoleukodystrophy Treatment Market Size by Application (2023-2028)
7.3.3 Europe Adrenoleukodystrophy Treatment Market Share by Application (2017-2028)
7.4 Europe Adrenoleukodystrophy Treatment Market Size by Country
7.4.1 Europe Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
7.4.2 Europe Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size (2017-2028)
8.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Type
8.2.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Adrenoleukodystrophy Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Application
8.3.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Adrenoleukodystrophy Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region
8.4.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Adrenoleukodystrophy Treatment Market Size (2017-2028)
9.2 Latin America Adrenoleukodystrophy Treatment Market Size by Type
9.2.1 Latin America Adrenoleukodystrophy Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Adrenoleukodystrophy Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Adrenoleukodystrophy Treatment Market Share by Type (2017-2028)
9.3 Latin America Adrenoleukodystrophy Treatment Market Size by Application
9.3.1 Latin America Adrenoleukodystrophy Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Adrenoleukodystrophy Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Adrenoleukodystrophy Treatment Market Share by Application (2017-2028)
9.4 Latin America Adrenoleukodystrophy Treatment Market Size by Country
9.4.1 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size (2017-2028)
10.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type
10.2.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application
10.3.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country
10.4.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 bluebird bio
11.1.1 bluebird bio Company Details
11.1.2 bluebird bio Business Overview
11.1.3 bluebird bio Adrenoleukodystrophy Treatment Introduction
11.1.4 bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.1.5 bluebird bio Recent Developments
11.2 Orpheris
11.2.1 Orpheris Company Details
11.2.2 Orpheris Business Overview
11.2.3 Orpheris Adrenoleukodystrophy Treatment Introduction
11.2.4 Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.2.5 Orpheris Recent Developments
11.3 MedDay Pharmaceuticals
11.3.1 MedDay Pharmaceuticals Company Details
11.3.2 MedDay Pharmaceuticals Business Overview
11.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.3.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.3.5 MedDay Pharmaceuticals Recent Developments
11.4 MINORYX THERAPEUTICS SL
11.4.1 MINORYX THERAPEUTICS SL Company Details
11.4.2 MINORYX THERAPEUTICS SL Business Overview
11.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Introduction
11.4.4 MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.4.5 MINORYX THERAPEUTICS SL Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adrenoleukodystrophy Treatment Introduction
11.5.4 Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.5.5 Pfizer Recent Developments
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Adrenoleukodystrophy Treatment Introduction
11.6.4 Amgen Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.6.5 Amgen Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Adrenoleukodystrophy Treatment Introduction
11.7.4 AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.7.5 AstraZeneca Recent Developments
11.8 Abbott
11.8.1 Abbott Company Details
11.8.2 Abbott Business Overview
11.8.3 Abbott Adrenoleukodystrophy Treatment Introduction
11.8.4 Abbott Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.8.5 Abbott Recent Developments
11.9 agtc
11.9.1 agtc Company Details
11.9.2 agtc Business Overview
11.9.3 agtc Adrenoleukodystrophy Treatment Introduction
11.9.4 agtc Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.9.5 agtc Recent Developments
11.10 ReceptoPharm
11.10.1 ReceptoPharm Company Details
11.10.2 ReceptoPharm Business Overview
11.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Introduction
11.10.4 ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.10.5 ReceptoPharm Recent Developments
11.11 The Myelin Project
11.11.1 The Myelin Project Company Details
11.11.2 The Myelin Project Business Overview
11.11.3 The Myelin Project Adrenoleukodystrophy Treatment Introduction
11.11.4 The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.11.5 The Myelin Project Recent Developments
11.12 SOM Biotech
11.12.1 SOM Biotech Company Details
11.12.2 SOM Biotech Business Overview
11.12.3 SOM Biotech Adrenoleukodystrophy Treatment Introduction
11.12.4 SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.12.5 SOM Biotech Recent Developments
11.13 Viking Therapeutics
11.13.1 Viking Therapeutics Company Details
11.13.2 Viking Therapeutics Business Overview
11.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Introduction
11.13.4 Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.13.5 Viking Therapeutics Recent Developments
11.14 Nutra Pharma Corporation
11.14.1 Nutra Pharma Corporation Company Details
11.14.2 Nutra Pharma Corporation Business Overview
11.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Introduction
11.14.4 Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.14.5 Nutra Pharma Corporation Recent Developments
11.15 Genetix Biotech
11.15.1 Genetix Biotech Company Details
11.15.2 Genetix Biotech Business Overview
11.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Introduction
11.15.4 Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.15.5 Genetix Biotech Recent Developments
11.16 Magenta Therapeutics
11.16.1 Magenta Therapeutics Company Details
11.16.2 Magenta Therapeutics Business Overview
11.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Introduction
11.16.4 Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.16.5 Magenta Therapeutics Recent Developments
11.17 NeuroVia
11.17.1 NeuroVia Company Details
11.17.2 NeuroVia Business Overview
11.17.3 NeuroVia Adrenoleukodystrophy Treatment Introduction
11.17.4 NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.17.5 NeuroVia Recent Developments
11.18 Novartis
11.18.1 Novartis Company Details
11.18.2 Novartis Business Overview
11.18.3 Novartis Adrenoleukodystrophy Treatment Introduction
11.18.4 Novartis Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.18.5 Novartis Recent Developments
11.19 CELGENE CORPORATION
11.19.1 CELGENE CORPORATION Company Details
11.19.2 CELGENE CORPORATION Business Overview
11.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Introduction
11.19.4 CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.19.5 CELGENE CORPORATION Recent Developments
11.20 Jazz Pharmaceuticals
11.20.1 Jazz Pharmaceuticals Company Details
11.20.2 Jazz Pharmaceuticals Business Overview
11.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.20.4 Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.20.5 Jazz Pharmaceuticals Recent Developments
11.21 Sanofi
11.21.1 Sanofi Company Details
11.21.2 Sanofi Business Overview
11.21.3 Sanofi Adrenoleukodystrophy Treatment Introduction
11.21.4 Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2017-2022)
11.21.5 Sanofi Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の副腎白質ジストロフィー治療市場インサイト及び予測（経口剤、経皮吸収型製剤）(Global Adrenoleukodystrophy Treatment Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の副腎白質ジストロフィー治療市場インサイト及び予測（経口剤、経皮吸収型製剤）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp